0001562180-23-004504.txt : 20230525
0001562180-23-004504.hdr.sgml : 20230525
20230525210134
ACCESSION NUMBER: 0001562180-23-004504
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230524
FILED AS OF DATE: 20230525
DATE AS OF CHANGE: 20230525
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hadas Nicole R.
CENTRAL INDEX KEY: 0001602396
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 23962761
MAIL ADDRESS:
STREET 1: 20 PILGRAM DRIVE
CITY: WINCHESTER
STATE: MA
ZIP: 01890
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0407
4
2023-05-24
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001602396
Hadas Nicole R.
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
SVP, Chief Legal Officer
false
Common Stock
2023-05-24
4
A
false
200000.00
0.00
A
587530.00
D
Common Stock
2023-05-25
4
S
false
63186.00
1.2229
D
524344.00
D
Employee Stock Option (Right to buy)
0.41
2023-05-24
4
A
false
200000.00
0.00
A
2032-05-12
Common Stock
200000.00
200000.00
D
As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs.
As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023.
/s/ Carolyn Rucci, attorney-in-fact for Nicole R. Hadas
2023-05-25